YAP1 and glioblastoma: However, in LGG or in GBM [with the R132H mutation in isocitrate dehydrogenase 1 (IDH1) which correlates with better GBM patient survival (Miroshnikova et al., 2016)], targeting YAP might be cautioned as YAP inhibition might promote tumor cell dissemination and metastasis (Sun et al., 2018).